US2021301001A1PendingUtilityA1

Antibody that binds murine wise protein

73
Assignee: STOWERS INSTITUTE FOR MEDICAL RESPriority: Jun 14, 2002Filed: Oct 15, 2020Published: Sep 30, 2021
Est. expiryJun 14, 2022(expired)· nominal 20-yr term from priority
Inventors:Robb KrumlaufDebra Ellies
A61K 2039/505C07K 14/705C07K 2317/34C07K 14/575A61K 48/00A01K 2217/05C07K 14/47C07K 2317/622C07K 14/4702C07K 2317/55A61K 38/00C07K 2317/76A01K 2227/105A61P 13/12C07K 2317/54A01K 2217/075C07K 2317/626C07K 16/30C07K 16/18
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.

Claims

exact text as granted — not AI-modified
1 .- 20 . (canceled) 
     
     
         21 . An isolated antibody that specifically binds to the contiguous amino acids of SEQ ID NO: 95. 
     
     
         22 . The isolated antibody of claim  1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a Fv fragment of an antibody, a Fab fragment of an antibody, a F(ab′)2 fragment of an antibody, a recombinant single chain Fv fragment (scFv), a diabody, a triabody, and a tetrabody. 
     
     
         23 . The isolated antibody of claim  1 , wherein the antibody is a monoclonal antibody. 
     
     
         24 . The isolated antibody of claim  1 , wherein the antibody is a polyclonal antibody. 
     
     
         25 . The isolated antibody of claim  1 , wherein the antibody is a Fv fragment of an antibody. 
     
     
         26 . The isolated antibody of claim  1 , wherein the antibody is a Fab fragment of an antibody. 
     
     
         27 . The isolated antibody of claim  1 , wherein the antibody is a F(ab′)2 fragment of an antibody. 
     
     
         28 . The isolated antibody of claim  1 , wherein the antibody is a recombinant single chain Fv fragment (scFv). 
     
     
         29 . The isolated antibody of claim  1 , wherein the antibody is a diabody. 
     
     
         30 . The isolated antibody of claim  1 , wherein the antibody is a triabody. 
     
     
         31 . The isolated antibody of claim  1 , wherein the antibody is a tetrabody.

Join the waitlist — get patent alerts

Track US2021301001A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.